We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 8 for:    Dapansutrile

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04971499
Recruitment Status : Recruiting
First Posted : July 21, 2021
Last Update Posted : September 13, 2022
Sponsor:
Collaborators:
Merck Sharp & Dohme LLC
Olatec Therapeutics LLC
Information provided by (Responsible Party):
April Salama, M.D., Duke University

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 30, 2023
Estimated Study Completion Date : April 30, 2024